4-(呋喃-2-羰基)-1,3-二氢咪唑-2-酮 | 77671-36-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(呋喃-2-羰基)-1,3-二氢咪唑-2-酮
• 英文名称: 1,3-dihydro-4-(2-furanoyl)-2H-imidazol-2-one
• 英文别名: 4-(Furan-2-carbonyl)-1,3-dihydro-2H-imidazol-2-one；4-(furan-2-carbonyl)-1,3-dihydroimidazol-2-one
• CAS: 77671-36-4
• 化学式: C₈H₆N₂O₃
• 分子量: 178.147
• InChiKey: UHMGFWJWRQMKFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1,3-二氢咪唑-2-酮 、 呋喃甲酰氯 在 三氯化铝 作用下， 以 硝基苯 为溶剂， 反应 6.0h， 以35%的产率得到4-(呋喃-2-羰基)-1,3-二氢咪唑-2-酮
  参考文献：
  名称：

  4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a new class of cardiotonic agents

  摘要：

  A series of 4-aroyl-1,3-dihydro-2H-imidazol-2-ones was synthesized and evaluated for pharmacological activity in the anesthetized dog. Most members of this series produced dose-related increases in cardiac contractile force as well as relatively minor increases in heart rate and decreases in systemic arterial blood pressure that were not blocked by propranolol. In general, 4-methoxy or 4-methylthiobenzoyl substitution afforded compounds of greatest inotropic potency. 1,3-Dihydro-4-(4-methoxybenzoyl)-5-methyl-2H-imidazol-one (6) was shown to produce a dose-related positive inotropic effect and reverse the depressant effect of pentobarbital on cardiac pump function in the dog heart-lung preparation. The cardiotonic activity of this series may have important utility in the treatment of congestive heart failure. 1,3-Dihydro-4-[4-(methylthio)benzoyl]-5-methyl-2H-imidazol-2-one (17) was chosen for human studies and is currently undergoing clinical trials.

  DOI：

  10.1021/jm00354a017

文献信息

• 4-Aroylimidazol-2-ones and their use as pharmaceuticals
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US04405635A1

  公开（公告）日：1983-09-20

  Novel 4-aroylimidazol-2-ones of the following general structure which are useful as antihypertensives, cardiotonics, antithrombotics, bronchodilators and uterospasmolytics ##STR1## wherein Ar is 2-furyl, 2-thienyl or phenyl, the latter of which may optionally be substituted with one or two X groups; X is halogen, hydroxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, methylenedioxy, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfoxide, C.sub.1-4 alkylsulfone, CF.sub.3, --SO.sub.2 N(R.sub.2).sub.2, NR.sub.3 R.sub.4, pyrrolidino, piperidino, morpholino, piperazino or N'-alkyl-piperazino, R is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkylcarbonyl or benzyl; each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are hydrogen or C.sub.1-4 alkyl; and the pharmaceutically acceptable salts thereof.

  以下是具有下列一般结构的4-芳酰基咪唑啉-2-酮类化合物，可用作降压药、心脏强心剂、抗血栓药、支气管扩张剂和子宫平滑肌松弛剂：##STR1##其中Ar为2-呋喃基、2-噻吩基或苯基，后者可以选择性地用一个或两个X基取代；X为卤素、羟基、C.sub.1-4烷基、C.sub.1-4烷氧基、亚甲二氧基、C.sub.1-4烷基硫基、C.sub.1-4烷基亚砜、C.sub.1-4烷基磺酰基、CF.sub.3、--SO.sub.2N(R.sub.2).sub.2、NR.sub.3R.sub.4、吡咯烷基、哌啶基、吗啉基、哌嗪基或N'-烷基哌嗪基，R为氢、C.sub.1-4烷基、C.sub.1-4烷基羰基或苄基；R.sub.1、R.sub.2、R.sub.3和R.sub.4中的每一个都是氢或C.sub.1-4烷基；以及其药学上可接受的盐。
• Novel 4-aroylimidazol-2-ones
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0058435A2

  公开（公告）日：1982-08-25

  Novel 4-aroylimidazol-2-ones of the following general structure which are useful as antihypertensives, cardiotonics and antithrombotics wherein Ar is 2-furyl, 2-thienyl or phenyl, the latter of which may optionally be substituted with one or two X groups; X is halogen, hydroxy, C1-4 alkyl, C1-4 alkoxy, methylenedioxy, C1-4 alkylthio, C1-4 alkylsulfoxide, C1-4 alkylsufone, CF3, -SO2N(R2)2, NR3R4, pyrrolidino, piperidino, morpholino, piperazino or N'-alkyl-piperazino, R is hydrogen, C1-4 alkyl, C1-4 alkylcarbonyl or benzyl; each of R1, R2, R3 and R4 are hydrogen or C1-4 alkyl; and the pharmaceutically acceptable salts thereof.

  具有以下一般结构的新型 4-芳基咪唑-2-酮，可用作抗高血压药、强心剂和抗血栓药 其中 Ar 是 2-呋喃基、2-噻吩基或苯基，后者可任选被一个或两个 X 基团取代；X 是卤素、羟基、C1-4 烷基、C1-4 烷氧基、亚甲基二氧基、C1-4 烷硫基、C1-4 烷基亚砜、C1-4 烷基砜、CF3、-SO2N(R2)2、NR3R4、吡咯烷基、哌啶基、吗啉基、哌嗪基或 N'- 烷基哌嗪基，R 是氢、C1-4 烷基、C1-4 烷基羰基或苄基；R1、R2、R3 和 R4 各为氢或 C1-4 烷基；及其药学上可接受的盐类。
• Novel aroylimidazolones
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0059948A1

  公开（公告）日：1982-09-15

  This invention relates to aroylimidazole-2-ones and their acid and base addition salts as well as their use as cardiotonics in the treatment of cardiac failure.

  本发明涉及甲酰基咪唑-2-酮及其酸和碱加成盐，以及它们作为治疗心力衰竭的强心剂的用途。
• SCHNETTLER, R. A.;DAGE, R. C.;GRISAR, J. M., J. MED. CHEM., 1982, 25, N 12, 1477-1481
  作者：SCHNETTLER, R. A.、DAGE, R. C.、GRISAR, J. M.

  DOI：——

  日期：——
• US4405628A
  申请人：——

  公开号：US4405628A

  公开（公告）日：1983-09-20